

1 **Rapid increase in SARS-CoV-2 seroprevalence during the emergence of** 2 **Omicron variant, Finland**

3 Ahava MJ¹, Jarva H^{1,2}, Jääskeläinen AJ¹, Lappalainen M¹, Vapalahti O^{1,3,4}, Kurkela S¹

4

5 ¹HUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki
6 University Hospital, Finland

7 ²Translational Immunology Research Program and Department of Bacteriology and Immunology,
8 University of Helsinki, Helsinki, Finland

9 ³Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

10 ⁴Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki,
11 Helsinki, Finland.

12

13 **Corresponding author:** Maarit Ahava

14 **Email:** maarit.ahava@hus.fi

15 **Address:**

16 Helsinki University Hospital,

17 HUSLAB, Virology and Immunology

18 P.O.B. 720 (Topeliuksenkatu 32)

19 FIN-00029 HUS, Finland

20 **Tel: +358 9 4711**

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 **Acknowledgements**

23 We would like to thank Ms. Irina Leino and Ms. Merja Heikkinen (Department of Virology and
24 Immunology, HUSLAB) for excellent technical assistance.

25

26 **Abstract**

27 Objectives

28 The aim of this study was to assess changes in exposure and prevalence of SARS-CoV-2 infection
29 during the first months of emergence of Omicron variant in the Greater Helsinki area, Finland.

30 Methods

31 A prospective seroepidemiological survey of SARS-CoV-2 was conducted on 1,600 serum
32 specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology between
33 15 November 2021 and 6 March 2022 (calendar weeks 46/2021 – 9/2022). For each calendar week,
34 100 serum specimens were randomly selected and analysed for SARS-CoV-2 IgG antibodies
35 against nucleocapsid (N) and spike 1 (S1) protein with Abbott SARS-CoV-2 IgG (N protein) and
36 SARS-CoV-2 IgG II Quant (S protein) tests, respectively.

37 Results

38 The prevalence of N antibodies increased from 5.2% (weeks 46-50/2021) to 28.2% (weeks 5-
39 9/2022) during the study period. The proportion of seronegative samples as well as anti-N negative,
40 anti-S1 positive samples decreased correspondingly from 11.6% to 3.8%, and 84.2% to 68.2%,
41 respectively. Anti-N positive samples that were anti-S1 negative only began to appear as of week
42 2/2022.

43 Conclusions

44 A rapid increase in the N antibody prevalence was observed over the study period, suggesting a
45 high transmission rate. A substantial proportion of COVID-19 cases remained undiagnosed during
46 the emergence of Omicron variant in the Greater Helsinki Area, Finland.

47 **Keywords:** COVID-19; SARS-CoV-2; serology; surveillance

48 The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) as of November 2021 changed the
49 epidemiology of COVID-19 with rapid upsurge of cases globally [1,2]. In Finland, the first patient
50 case with Omicron variant was detected on 29 November 2021 [3]. In this study, we conducted a
51 prospective seroepidemiological survey of SARS-CoV-2 in November 2021 – March 2022 in the
52 Greater Helsinki area, Finland. Our aim was to assess changes in exposure and prevalence of
53 SARS-CoV-2 infection during the first months of emergence of Omicron variant.

54 The study was institutionally approved (HUS/56/2021). Altogether 1,600 serum specimens were
55 analyzed with Abbott SARS-CoV-2 IgG II Quant (IgG antibodies to receptor binding domain
56 (RBD) of the S1 subunit of the S protein of SARS-CoV-2) and N antibodies with Abbott SARS-
57 CoV-2 IgG (IgG antibodies to N protein of SARS-CoV-2) on the Alinity i analyzer. The sampling
58 scheme included 100 specimens each week between weeks 46/2021 and 9/2022, from routine
59 samples sent to HUS Diagnostic Center, Helsinki. The sampling frame comprised 17,000 serum
60 specimens that were tested negative for HIV Ag/Ab between 15 November 2021 and 6 March 2022
61 and stored according to date of specimen. To select samples for each calendar week, a random
62 starting point was chosen, and specimens were systematically selected until 100 specimens plus 5
63 spare samples were reached: the chosen 100 specimens were analyzed for SARS-CoV-2 antibodies.
64 If the analysis failed or the specimen volume was not adequate, the sample was replaced by one of
65 the spare samples of that calendar week.

66 The subgroups identified according to serostatus were I) anti-N negative, anti-S1 negative: no
67 serological evidence of vaccine immunization or previous infection; II) anti-N negative, anti-S1
68 positive: seroresponse to vaccine immunization, no evidence of recent infection; III) anti-N
69 positive, anti-S1 positive: consistent with previous infection, vaccine immunization status
70 unknown; IV) anti-N positive, anti-S1 negative: recent infection possible, no evidence of vaccine
71 immunization. The proportion of these subgroups was determined for each calendar week and

72 statistical analyses were performed using IBM SPSS statistical program package, version 25.,
73 visualization was done with GraphPad Prism 8.0.1.

74 The study subjects' age ranged from 11 months to 94 years (median 33 years; IQR 26-46 years),
75 and the proportion of women was 55.2%. The baseline prevalence of N antibodies in the first five
76 weeks of the study period (46-50/2021) was 5.2%, while in the final five weeks (5-9/2022) it was
77 28.2%. The proportion of seronegative samples for the corresponding time frames was 11.6% and
78 3.8%, and for anti-N negative, anti-S1 positive samples 84.2% and 68.2%. Figure 1 depicts the
79 moving average of the N antibody seroprevalence over the study period: the sharpest increase was
80 observed in those aged <30 years. In late 2021, the seroprevalence of N antibodies was consistently
81 well below 10% but began a rapid incline as of week 1/2022 and surpassed 20% on week 3/2022.

82 Anti-N positive samples that were anti-S1 negative began to appear on week 2/2022 and
83 represented 0.9% (14/1600) of all analyzed samples, which may reflect a diminished or delayed
84 seroresponse against S1 during Omicron infection. The increase in anti-N positive samples (groups
85 III and IV) was reflected as a decreasing proportion of seronegative samples (group I) towards the
86 end of the study period. The proportions of subgroups (I-IV) per calendar week are presented in
87 Figure 2.

88 By mid-December 2021, Omicron had become the primary variant in the Greater Helsinki area [3].
89 Soon after, our data show a rapid increase in the population level exposure to SARS-CoV-2. This
90 indicates a high transmission rate and is in line with previous reports from elsewhere [4,5,6]. At the
91 end of the study period (week 9/2022), 4% were seronegative in N and S antibody testing.

92 Altogether 78% (1241/1600) had S antibodies without N antibodies, suggesting vaccine
93 immunization without recent COVID-19 infection.

94 Our study design did not allow differentiation between those who had undergone COVID-19 with
95 or without prior vaccine immunization. Also, protective immunity against SARS-CoV-2 cannot be

96 determined by detection of antibodies to N or S antigen by enzyme immunoassays. As the purpose
97 of this study was to provide real-time data, conducting neutralization assays was not feasible.

98 The present study showed a rapid increase in the N antibody prevalence, indicating that
99 approximately 23% (comparing the first and last five weeks of the study period) of the tested
100 individuals had contracted SARS-CoV-2 infection during the emergence of Omicron variant. While
101 our sampling frame does not perfectly reflect the general population, the data suggest that during
102 the study period, well beyond 300,000 individuals in the Greater Helsinki area (population 1.5
103 million inhabitants) underwent COVID-19, while at the same time approximately 230,000 COVID-
104 19 cases were officially diagnosed in Greater Helsinki [7]. The present study suggests that a
105 substantial proportion of COVID-19 cases remained undiagnosed during the emergence of
106 Omicron, probably due to subclinical infections and diminished RT-PCR testing.

107

108 **Conflict of interest:** None of the authors have conflict of interest.

109 **Funding statement:** Funded by Helsinki University and Helsinki University Hospital, HUSLAB,
110 Helsinki, Finland (TYH2021110, TYH2021343, Y780022023 and Y780022035).

111 **Contribution:**

112 MA: Maarit Ahava; HJ: Hanna Jarva; AJ: Annemarjut J Jääskeläinen; ML: Maija Lappalainen; OV:
113 Olli Vapalahti; SK: Satu Kurkela

114 Conceptualisation: HJ, OV, SK. Data curation: MA, HJ, SK. Formal analysis: MA, HJ, SK.

115 Investigation: MA, HJ, AJ, ML, OV, SK. Methodology: MA, AJ, SK. Project administration: HJ,

116 SK. Resources: ML. Validation: MA, HJ, AJ, ML, OV, SK. Writing - original draft: MA, SK.

117 Writing - review & editing, MA, HJ, AJ, ML, OV, SK. All authors approved the final version of the
118 manuscript.

119 **Data availability:**

120 The datasets generated during and/or analysed during the current study are available from the
121 corresponding author.

122

123

124 **References**

- 125 1. ECDC. Assessment of the further emergence and potential impact of the SARS-
126 CoV-2 Omicron variant of concern in the context of ongoing transmission of the
127 Delta variant of concern in the EU/EEA, 18th update. Published online 2021.
- 128 2. WHO Coronavirus (COVID-19) Dashboard. Accessed March 23, 2022.
129 <https://covid19.who.int/>
- 130 3. Vauhkonen H, Truong P, Kant R et al. Introduction and rapid spread of SARS-
131 CoV-2 Omicron variant and the dynamics of its sub-lineages BA.1 and BA.1.1,
132 December 2021, Finland, 23 March 2022, PREPRINT (Version 1) available at
133 Research Square. doi: 10.21203/rs.3.rs-1480433/v1
- 134 4. Baker JM, Nakayama JY, O’Hegarty M, et al. SARS-CoV-2 B.1.1.529 (Omicron)
135 Variant Transmission Within Households — Four U.S. Jurisdictions, November
136 2021–February 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(9):341-346.
137 doi:10.15585/MMWR.MM7109E1 1.
- 138 5. Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2
139 Omicron variant in Norway, November to December 2021. *Eurosurveillance.*
140 2021;26(50):2101147. doi:10.2807/1560-7917.ES.2021.26.50.2101147
- 141 6. Song JS, Lee J, Kim M, et al. Serial Intervals and Household Transmission of
142 SARS-CoV-2 Omicron Variant, South Korea, 2021 - Volume 28, Number 3—
143 March 2022 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis.*
144 2022;28(3):756-759. doi:10.3201/EID2803.212607
- 145 7. THL, National Institute for Health and Welfare : National infectious disease
146 register. Accessed March 23, 2022.
147 [https://sampo.thl.fi/pivot/prod/fi/epirapo/covid19case/fact_epirapo_covid19case;js](https://sampo.thl.fi/pivot/prod/fi/epirapo/covid19case/fact_epirapo_covid19case;jsessionid=6A49E7FCD1DCCEB303F35730221824F1.apps5?row=dateweek20200)
148 [essionid=6A49E7FCD1DCCEB303F35730221824F1.apps5?row=dateweek20200](https://sampo.thl.fi/pivot/prod/fi/epirapo/covid19case/fact_epirapo_covid19case;jsessionid=6A49E7FCD1DCCEB303F35730221824F1.apps5?row=dateweek20200)

149

101-509030&column=measure-

150

444833.445356.492118.&fo=1&filter=hcdmunicipality2020-445193

151

152 FIGURE LEGENDS


153 Figure 1: Proportion of N antibody positive samples, three-week moving average. 1a: All samples
154 from all age groups, N=1600, 1b: Study subjects under 30 years, N=616 1c: study subjects 30-45
155 years, N=580, 1d: study subjects over 45 years, N=404.

156

157 Figure 2: Proportions of subgroups over the study period. The increase in N antibody positive
158 samples was reflected as a decreased proportion of both the group of completely seronegative
159 samples and samples of immunized individuals.

160


161 Figure 1: Proportion of N antibody positive samples, three-week moving average



162

163

164 Figure 2: Proportions of subgroups



165

166

167

168

169

170

171